Kellerhals Carrard advised Vifor Pharma on the transaction. Vischer advised Inositec on the deal. Vifor Pharma acquired the Swiss firm Inositec AG, a clinical stage biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Vischer advised GlycoEra AG on the deal. Walder Wyss advised 5AM Ventures, Roche Venture Fund and Sofinnova Partners as lead investors. GlycoEra AG has closed CHF...
You must be a Standard 1 Year member to access this content.
Vischer advised MiniNaviDent AG in the transaction. MiniNaviDent has received an investment by Straumann Holding AG to further develop and market its DENACAM system, a miniaturized...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Bachem Holding on the deal. Bachem Holding AG (SIX:BANB) has raised CHF 583.5m through an accelerated bookbuilding process by issuing 750,000 new shares...
You must be a Standard 1 Year member to access this content.
VISCHER advised Anjarium Biosciences on the deal. Baker McKenzie advises a consortium of life science funds, including Abingworth and Gimv, alongside Omega Funds, Pfizer Ventures and...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...
You must be a Standard 1 Year member to access this content.
VISCHER AG advises Polyphor AG on the deal. Walder Wyss advises Enbiotix Inc. on this transaction. Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
You must be a Standard 1 Year member to access this content.
VISCHER has advised TargImmune on the deal. TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused...
You must be a Standard 1 Year member to access this content.
VISCHER AG has advised Novartis AG in this transaction. Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching...
You must be a Standard 1 Year member to access this content.
Vischer assisted Swiss Nuclides in this transaction . Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, has raised CHF 2.6m...
You must be a Standard 1 Year member to access this content.
Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments. Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to...
You must be a Standard 1 Year member to access this content.
